Antithrombotic effects of losartan in patients with hypertension complicated by atrial fibrillation: 4A (Angiotensin II Antagonist of platelet Aggregation in patients with Atrial fibrillation), a pilot study

Hypertension Research

Volumn 37, Issue 6, 2014, Pages 513-518

  Sakamoto, Tomohiro ^a   Kudoh, Takashi ^b   Sakamoto, Kenji ^b   Matsui, Kunihiko ^c   Ogawa, Hisao ^b  

^a SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

losartan; platelet aggregation; type 1 plasminogen activator inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR; LOSARTAN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; VON WILLEBRAND FACTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ARTICLE; DOSE RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PILOT STUDY; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT DURATION; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; HYPERTENSION; METABOLISM; MIDDLE AGED; RISK FACTOR; THROMBOEMBOLISM; TIME; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PILOT PROJECTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION; RISK FACTORS; THROMBOEMBOLISM; THROMBOPLASTIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901988068     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.22     Document Type: Article

References (33)

1. Kawano H, Soejima H, Kojima S, Kitagawa A, Ogawa H, Japanese Acute CoronarySyndrome Study (JACSS) Investigators. Sex differences of risk factors for acutemyocardial infarction in Japanese patients. Circ J 2006; 70: 513-517.
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, andpredisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol1998; 82: 2N-9N.
3. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary arterydisease and the acute coronary syndromes. New Engl J Med 1992; 326: 242-250.
4. Pritchett EL. Management of atrial fibrillation. N Engl JMed 1992; 326: 1264-1271.
5. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediatedcardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
6. Dahlö f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, LIFE Study Group. Cardiovascular morbidity and mortality in thelosartan intervention for endpoint reduction in hypertension study (LIFE); a randomisedtrial against atenolol. Lancet 2002; 359: 995-1003.
7. Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlö f B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB. Cardiovascular morbidity and mortality in hypertensive patients with ahistory of atrial fibrillation: the Losartan Intervention For End Point Reduction inHypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705-711.
8. Guerra-Cuesta JI, Montón M, Rodr?́guez-Feo JA, Jiménez AM, González-Fernández F, Rico LA, Garc?́a R, Gómez J, Farré J, Casado S, López-Farré A. Effect of losartan onhuman platelet activation. J Hypertens 1999; 17: 447-452.
9. Li-Saw-Hee FL, Beevers DG, Lip GY. Effect of antihypertensive therapy using enalaprilor losartan on haemostatic markers in essential hypertension: a pilot prospectiverandomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-246.
10. Soejima H, Ogawa H, Suefuji H, Kaikita K, Takazoe K, Miyamoto S, Kajiwara I, Shimomura H, Sakamoto T, Yoshimura M, Nakamura S. Comparison of effects oflosartan versus enalapril on fibrinolysis and coagulation in patients with acutemyocardial infarction. Am J Cardiol 2001; 87: 1408-1411.
11. Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of plateletaggregates with a particle counting method using light scattering. Anal Biochem 1994;218: 284-294.
12. Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, Soejima H, Kugiyama K, Yoshimura M, Yasue H. Rapid change of platelet aggregability in acutehyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost2000; 83: 475-479.
13. Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition ofplatelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86:1188-1192.
14. Krämer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, Tsikas D, Böger RH, Forssmann WG, Drexler H, Schieffer B. Angiotensin II receptor-independentantiinflammatory and antiaggregatory properties of losartan: role of the activemetabolite EXP3179. Circ Res 2002; 90: 770-776.
15. Remková A, Remko M. The role of renin-angiotensin system in prothrombotic state inessential hypertension. Physiol Res 2010; 59: 13-23.
16. Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oralanticoagulant drugs for efficacy and safety when used for stroke prevention in atrialfibrillation. J Am Coll Cardiol 2012; 60: 738-746.
17. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, Murohara T.Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation:involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128:e113-e118.
18. Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006; 20: 101-108.
19. Okada H, Watanabe Y, Kikuta T, Kobayashi T, Kanno Y, Sugaya T, Suzuki H. Bradykinindecreases plasminogen activator inhibitor-1 expression and facilitates matrix degradationin the renal tubulointerstitium under angiotensin-converting enzyme blockade.J Am Soc Nephrol 2004; 15: 2404-2413.
20. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endotheliumderivedrelaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92: 181-187.
21. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients withatrial fibrillation. New Engl J Med 2011; 364: 928-938.
22. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrentatrial fibrillation. New Engl J Med 2009; 360: 1606-1617.
23. Markel A, Brook JG, Levy Y, Aviram M, Youdim MB. Increased platelet adhesion andaggregation in hypertensive patients: effect of atenolol. Br J Clin Pharmacol 1983; 16:663-668.
24. Montón M, Jiménez A, Núñ ez A, López-Blaya A, Farré J, Gómez J, Zalba LR.Sánchez de Miguel L, Casado S, López-Farré A. Comparative effects of angiotensinII AT-1-type receptor antagonists in vitro on human platelet activation. J CardiovascPharmacol 2000; 35: 906-913.
25. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondaryprevention of vascular disease: collaborative meta-analysis of individual participantdata from randomised trials. Lancet 2009; 373: 1849-1860.
26. Miyamoto S, Ogawa H, Soejima H, Takazoe K, Kajiwara I, Sakamoto T, Yoshimura M, Kugiyama K, Yasue H. Increased rate of formation of small-sized platelet aggregates inpatients with acute coronary syndromes. Jpn Circ J 2000; 64: 647-652.
27. Kudoh T, Sakamoto T, Miyamoto S, Matsui K, Kojima S, Sugiyama S, Yoshimura M, Ozaki Y, Ogawa H. Relation between platelet microaggregates and ankle brachial indexin patients with peripheral arterial disease. Thromb Res 2006; 117: 263-269.
28. Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlö f B, LIFE Study Group. The effect oflosartan versus atenolol on cardiovascular morbidity and mortality in patients withhypertension taking aspirin: the Losartan Intervention for Endpoint Reduction inhypertension (LIFE) study. J Am Coll Cardiol 2005; 46: 770-775.
29. Sakamoto T, Yasue H, Ogawa H, Misumi I, Masuda T. Association of patency of theinfarct-related coronary artery with plasma levels of plasminogen activator inhibitoractivity in acute myocardial infarction. Am J Cardiol 1992; 70: 271-276.
30. Hirashima O, Ogawa H, Oshima S, Sakamoto T, Honda Y, Sakata S, Masuda T, Miyao Y, Yasue H. Serial changes of plasma plasminogen activator inhibitor activity in acutemyocardial infarction: difference between thrombolytic therapy and direct coronaryangioplasty. Am Heart J 1995; 130: 933-939.
31. Takazoe K, Ogawa H, Yasue H, Sakamoto T, Soejima H, Miyao Y, Kawano H, Moriyama Y, Misumi K, Suefuji H, Kugiyama K, Yoshimura M. Increased plasminogenactivator inhibitor activity and diabetes predict subsequent coronary events in patientswith angina pectoris. Ann Med 2001; 33: 206-212.
32. Erdem Y, Usalan C, Haznedarog?lu IC, Altun B, Arici M, Yasavul U, Turgan C, Cag?lar S.Effects of angiotensin converting enzyme and angiotensin II receptor inhibition onimpaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 12:1071-1076.
33. Goodfield NE, Newby DE, Ludlam CA, Flapan AD. Effects of acute angiotensin II type 1receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolyticparameters in patients with heart failure. Circulation 1999; 99: 2983-2985.